What the clinical evidence actually shows

The most practical question at this stage is straightforward: how much improvement can the ChondroFiller injection actually deliver, and will it last?

Across four distinct prospective studies summarised in the manufacturer's Version 09 Clinical Evaluation Report (CER, April 2025), knee outcomes show a consistent pattern. Mean IKDC score improvements of approximately 30 points were recorded — exceeding the established Minimal Clinically Important Difference of 16.7 points in every study. The most granular data come from the Jerosch et al. post-market clinical follow-up study, which tracked patients to three years and found that a mean improvement of 32.4 points was not only sustained but slightly increased, with patients reaching a functional score of 80.

Three years is the ceiling of published, quantified follow-up for ChondroFiller specifically. Five-year outcome data have not been publicly reported. That is an important boundary to acknowledge: the existing evidence is consistent and clinically meaningful, but a patient asking whether the benefit lasts a decade cannot yet be answered from the published record.

The evidence base is predominantly manufacturer-sponsored cohort data; no randomised controlled trials against active comparators have been published. Prospective cohort studies at three years across four separate investigations carry real weight — but that distinction matters when calibrating how strongly the findings can be interpreted.

More than 19,000 ChondroFiller cases have been performed globally, spanning knee, hip, ankle, and small joints. What those results look like joint by joint is covered in the sections below.

How the ChondroFiller injection works

Delivered as an outpatient ultrasound-guided injection at the London Cartilage Clinic, ChondroFiller is an acellular Type I collagen scaffold — murine-derived and free of living cells — that self-gels within the cartilage defect shortly after placement.

The mechanism is acellular matrix-induced chondrogenesis. Rather than introducing new cells directly, the scaffold creates a chemotactic environment that draws the patient's own progenitor cells in from surrounding tissue. Those cells differentiate into chondrocytes and progressively build new cartilage matrix as the collagen scaffold is resorbed and replaced.

This biological timeline is visible on MRI. In one key study, MOCART scores — a validated measure of defect fill and repair-tissue integration — rose from 65.3 at four weeks to 81.6 at one year, reflecting the gradual maturation of repair tissue rather than an immediate structural change. 'Success' in this context means a defect that is progressively filled with organised repair tissue, not an overnight result.

No surgical incision or arthroscopic port is involved; the entire procedure takes place in a clinic setting under ultrasound guidance.

Knee outcomes at three years

Structural MRI evidence provides an objective counterpart to the functional scores covered in the opening section. The relevant measure is MOCART — a validated cartilage MRI scoring system that rates defect fill, repair-tissue integration with surrounding native cartilage, and surface congruency on a 0–100 scale.

By the time patients reach established follow-up in European cohort studies, MOCART scores range from 81.6 to 84.3, indicating more than 80% defect fill and good border integration of the repair tissue. Across the full published dataset — spanning different study populations and follow-up timepoints — values range from 70 to 87. The spread within that band reflects differences in defect characteristics, patient selection, and precisely when in the repair timeline the scan was taken; scores recorded at four weeks inevitably sit lower than those taken at twelve months as the repair tissue matures.

The Jerosch PMCF study, which provides the longest tracking, shows that by three years the cohort reached a mean IKDC of 80 — the endpoint score rather than the change from baseline — and that this figure held or marginally improved on earlier readings. Structural and patient-reported trajectories therefore align: neither shows sharp deterioration within the published window.

Three years is where published quantified data end. No MRI or patient-reported outcome figures at four or five years have been publicly reported for ChondroFiller injection. Within the period studied the evidence is consistent and clinically meaningful; durability beyond that horizon remains to be established by longer-term follow-up.

Hip and small joint outcomes

Beyond the knee, the evidence base spans hip, wrist, and small upper-limb joints, with ankle and shoulder also represented in the clinical record.

In the hip, studies in patients with focal cartilage damage and femoroacetabular impingement (FAI) report a mean Harris Hip Score improvement of approximately 33 points. That is comparable in magnitude to the IKDC gains documented in knee populations and crosses a threshold that patients tend to notice: reduced groin pain during walking, easier rotation when getting in and out of a car, and greater confidence on stairs.

For small joints — wrist and upper limb — the reported outcomes translate into tangible functional gains: reduced pain on the NRS scale, improved scores on the DASH (Disabilities of the Arm, Shoulder and Hand) questionnaire, and measurable increases in grip and pincer strength. MRI confirms the structural basis for those improvements: reduced bone marrow oedema, diminished joint effusion, and visible joint space widening over the follow-up period.

Ankle and shoulder data exist within the published record, though the evidence there is less voluminous and quantitative headline figures are thinner than for the knee or hip.

One important qualifier applies across all non-knee joints: outcomes in smaller or differently loaded joints may not mirror those seen in the knee, and published follow-up data for hip and small joint indications do not yet extend beyond three years.

What influences your results

Several factors shape how well the scaffold integrates and how much functional recovery patients experience — and a clinician will weigh each of these at assessment rather than applying a single threshold.

Defect size and containment matter considerably. Smaller, well-bounded focal defects give the collagen matrix a stable environment in which to gel and retain host cells; larger or poorly contained lesions present a more demanding repair problem. The quality of the cartilage immediately surrounding the defect has a parallel effect: healthy adjacent tissue supports scaffold integration, whereas softened or degraded borders may limit how completely the repair tissue knits in.

Mechanical instability is the single factor that most reliably undermines results. If a joint carries untreated ligament laxity or significant malalignment, the scaffold is placed into a biomechanical environment that continually stresses the repair site. ChondroFiller injection addresses the cartilage defect, not the underlying mechanics; where instability is present and left unmanaged, it tends to offset the benefit of the scaffold regardless of how well the procedure itself is performed.

Overall patient suitability and indication are closely linked to outcome. The injectable scaffold can be used across a wide spectrum of joint wear — including more advanced, diffuse changes — but the appropriate indication for each patient is determined at consultation. A minority of patients do not achieve the level of regeneration that most experience, which is why individualised assessment rather than a blanket referral pathway is the right starting point.

Getting an assessment in London

Suitability for the injectable scaffold pathway depends on clinical variables that imaging alone cannot resolve — defect geometry, surrounding cartilage condition, joint loading, and the presence or absence of mechanical instability all factor into whether the ChondroFiller injection is the right intervention and what outcome is realistic. Placement accuracy also carries independent weight: the collagen matrix must be deposited precisely within the lesion for it to gel and retain host progenitor cells effectively, which means the skill of the injecting clinician is not incidental to the result.

In the UK, Liquid Cartilage™ (ChondroFiller injection) is delivered at the London Cartilage Clinic on Harley Street. Professor Paul Y. F. Lee leads that service and brings particular experience in image-guided scaffold placement across knee, hip, and small-joint indications. For patients with a confirmed or suspected focal cartilage defect who want to understand whether this pathway is appropriate for their joint, the starting point is a structured clinical assessment — further information and appointment enquiries at londoncartilage.com.